Clal Biotechnology Industries Ltd. (CBI) unit CureTech Ltd. received FDA approval for a Phase II clinical trial for a third indication for its drug technology.
The study will measure the efficacy of the company's flagship product, an antibody that stimulates an anti-cancer immune response against several forms of cancer, in treatment of non-Hodgekin's lymphoma.
Lire la suite »
Anti Boycott Israel blog
Source: article de Gali Weinreb @ Globes